Soligenix announced preliminary top-line results of its ongoing Phase 2a trial of SGX302 – synthetic hypericin – for the treatment of mild-to-moderate psoriasis. In the expanded portion of the trial, an additional five patients were enrolled. The Cohort 2 patients were treated more aggressively than the patients enrolled in Cohort 1 during an 18-week treatment period. SGX302 therapy was well tolerated by all patients with no drug related adverse events identified. In the four evaluable patients from Cohort 2, two reached a disease status of “Almost Clear”. In addition, the Psoriasis Activity and Severity Index score for patients in Cohort 2 had a mean drop of approximately 50% over the 18-week treatment. The company anticipates continuing to pursue SGX302 in psoriasis as it completes discussions with the FDA and the European Medicines Agency regarding a feasible confirmatory trial design for HyBryte in the treatment of early-stage CTCL.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNGX:
- Soligenix anounces publication showing efficacy of ebolavirus and MARV vaccine
- Soligenix rallies after Chief Scientific Officer authors paper in ScienceDirect
- Soligenix jumps170% after FDA clears IND application for dusquetide in Behcet’s
- Soligenix’s dusquetide granted FDA IND clearance for Phase 2 trial in Behcet’s
- Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results
